CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Aggressive Measures to Decrease "Door to Balloon" Time and Incidence of Unnecessary Cardiac Catheterization: Potential Risks and Role of Quality Improvement Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China Bare metal versus drug eluting stents for ST-segment elevation myocardial infarction in the TOTAL trial Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES

Guidelinehttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa575/5898842

JOURNAL:Eur Heart J. Article Link

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

J-P Collet, H Thiele, E Barbato et al. Keywords: ACS without persistent ST-segment elevation; Guidelines; acute cardiac care; angioplasty; anticoagulation; antiplatelet; apixaban; aspirin; atherothrombosis; betablockers; bleedings; bivalirudin; CABG; cangrelor; chest pain unit; clopidogrel; dabigatran; diabetes; DAPT; early invasive strategy; edoxaban; enoxaparin; fondaparinux; glycoprotein IIb/IIIa inhibitors; heparin; high-sensitivity troponin; MINOCA; myocardial ischaemia; MI; nitrates; platelet inhibition; prasugrel; revascularization; rhythm monitoring; rivaroxaban; stent; ticagrelor; triple therapy; unstable angina

Full Text PDF